Related Experiment Video
Updated: Jun 10, 2025
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review
John L Petrie1, Charlie A Smith2, Donna Fountain1
1Putnam, Portland House, New Bridge Street West, Newcastle Upon Tyne, NE1 8AP, UK.
Neurology and Therapy
|October 19, 2024
Summary
Real-world studies show ocrelizumab persistence is similar to or better than clinical trials for multiple sclerosis. Ocrelizumab discontinuation rates due to adverse events were low, with higher adherence compared to other disease-modifying therapies.
Area of Science:
- Neurology
- Pharmacology
- Real-world evidence
Background:
- Clinical trial data for ocrelizumab in multiple sclerosis (MS) showed low discontinuation rates due to adverse events.
- Real-world patient populations differ from clinical trial participants, necessitating real-world data assessment.
- Understanding treatment persistence and discontinuation is crucial for managing MS effectively.
Purpose of the Study:
- To conduct a systematic literature review (SLR) of real-world studies.
- To identify discontinuation and persistence data for ocrelizumab in relapsing remitting MS (RRMS) and primary progressive MS (PPMS).
- To compare real-world ocrelizumab data with pivotal clinical trial findings.
Main Methods:
- Searches of MEDLINE and Embase databases were performed.
- Relevant real-world studies meeting PICOS criteria were included.
- Only English-language articles were considered.
Main Results:
- Thirty studies were included in the review.
- Most studies reported real-world ocrelizumab persistence comparable to or exceeding clinical trial results.
- One study reported higher discontinuation rates for ocrelizumab due to adverse events compared to clinical trials.
- Ocrelizumab demonstrated lower discontinuation risk and higher adherence compared to other disease-modifying therapies (DMTs).
Conclusions:
- Real-world persistence and discontinuation data for ocrelizumab in MS are generally favorable.
- Ocrelizumab may offer advantages in adherence and persistence over other DMTs.
- Findings support the clinical relevance of treatment persistence for improved outcomes and cost-effectiveness in MS management.
Related Concept Videos
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:06Drug Clearance: Overview
57
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
57
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97